A. Briganti

Local treatment vs. years of life lost in intermediate-risk prostate cancer

The role of radical prostatectomy (RP) or radiotherapy (RT) in intermediate-risk prostate cancer (PCa) is still under debate. Our aim was to quantify the effect of RP and RT on the average years of life lost (YLL) in patients with intermediate-risk PCa. Within the SEER database 2004–2021, intermediate-risk PCa patients...

ASO Visual Abstract: Cancer-Specific Mortality in Rare Histologic Subtypes of Prostate Cancer: Radical Prostatectomy Versus Radiation Therapy

Epidemiology, Risk Factors, and Prevention of Prostate Cancer.

Rare prostate cancer histologies: detection, characteristics and treatment.

Cancer-specific mortality in high-risk or very high-risk prostate cancer patients treated with cryotherapy vs. external beam radiation therapy

Stage migration in prostate cancer: the role of PSMA-PET in identifying oligometastatic disease.

Positive surgical margins after partial nephrectomy across changing surgical eras: long-term oncological results from a tertiary referral center

Long-term Oncological Outcomes of Retzius-sparing Versus Anterior Robot-assisted Radical Prostatectomy: Post Hoc Analysis of a Randomized Cohort.

Although RS RARP provides superior early continence outcomes, patients randomized to this approach experienced less favorable long-term oncological control, potentially because of the increased technical demands of the procedure.

Immunohistochemical stratification of bladder small cell carcinoma reveals two major phenotypes with distinct therapeutic biomarker profiles.

Low membranous Nectin-4 expression and preferential DLL3 and SLFN11 expression in High-NE tumours support further investigation of alternative therapeutic strategies, and SmCCB may be stratified into two IHC-defined phenotypic groups with distinctive neuroendocrine differentiation and therapeutic biomarker profiles.

Cancer-specific mortality in high-risk or very high-risk prostate cancer patients treated with focal therapy vs. radical prostatectomy.

INTRODUCTION Focal therapy (FT) in high-risk or very high-risk prostate cancer (CaP) is not guideline-recommended. However, it may be occasionally used, but its effect on cancer-specific mortality (CSM) relative to standard treatment options such as radical prostatectomy (RP) is unknown and was addressed in the present...

Diet and risk of bladder cancer: a systematic review of epidemiological evidence.

Available evidence does not support a strong or consistent association between dietary factors and bladder cancer (BC) risk, and patients should be informed that dietary modifications alone are unlikely to meaningfully alter their BC risk.